The iCMLf is sharing a selection of interesting scientific publications on COVID-19 and CML from peer-reviewed journals.

Latest publications on COVID-19 and CML/Cancer

Papers on COVID-19 and CML

• COVID-19 in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy:
  a Honduran obervational study
  Fajardo CJ et al. ecancer Med Sci, December 2022
• Impact of the COVID-19 pandemic on the regular follow-up and outcomes of patients with chronic myeloid leukemia in chronic-phase
  Yilmaz U et al. Front Oncol, Oct 2022 – open access publication
• Incidence of symptomatic COVID-19 infection in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population
  Graf I et al. Eur J Hematol, Oct 2022 (epub ahead of print) – open access publication
• Role of tyrosine kinase inhibitor in chronic myeloid leukemia patients with SARS-CoV-2 infection: A narrative Review
  Asif M et al. Medicine (Baltimore), July 2022 – open access publication
• SARS-CoV-2 Omicron variant in patients with chronic myeloid leukemia: A retrospective study
  Ali EA et al. Cereus, April 2022 – open access publication
• What do we currently know about chronic myeloid leukemia (CML) and COVID-19?
  Delgado N and Torres A. Curr Oncol Rep, February 2022 (epub ahead of print) - open access publication
• Long-term persistence of natural anti-SARS-CoV2 antibodies and mild impact of SARS-CoV2 infection in CML patients: results from a seroprevalance study
  Claudiani S et al. Leuk Lymphoma, January 2022 (epub ahead of print)

Papers on COVID-19 vaccines and CML

• COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
  Milojkovic D et al. Leukemia, December 2022 (epub ahead of print) – open access publication
• Antibody responses post-COVID-19 vaccination in patients with chronic myeloid leukemia in comparison between Comirnaty and CoronaVac Vaccine
  Kuan JW et al. Asia Pac J Public Health, July 2022
• Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic leukemia patients on tyrosine kinase inhibitors
  Claudiani S et al. Br J Haematol, December 2021 (epub ahead of print) – open access publication
• Single dose BNT162b1 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with CML
  Harrington P et al. Br J Haematol, June 2021 (epub ahead of print) – open access publication

Papers on COVID-19 and hematological malignancies

• COVID-19 in patients with haematological malignancies (HM) – Clinical manifestations, persistence and immune response
  Gur I et al. Acta Hematol, March 2022 (epub ahead of print) – open access publication
• Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
  Buske C et al. ESMO Open, April 2022 (epub ahead of print) - open access publication

Papers on COVID-19 vaccines and hematological malignancies

• COVID-19 and blood cancer in the vaccination era
  Hicks LK and Vijenthira A. Blood, December 2022
• Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
  Pagano L et al. Blood, December 2022
• Anti-spike T-cell and antibody responses to SARS-CoV-2 mRNA vaccines in patients with hematologic malignancies
  Greenberger LM et al. Blood Cancer Discov, November 2022
• Induction of robust humoral Immunity against SARS-CoV-2 after vaccine administration in previously infected haematological cancer patients
  Borgogna C et al. Br J Haematol, November 2022 – open access publication
  
• Antibody status following booster vaccination against SARS-CoV-2 virus in patients with haematological malignancies
  Ikeda D et al. Br J Haematol, November 2022 (epub ahead of print)
• Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey
  Pagano L et al. Blood, September 2022 (epub ahead of print) – open access publication
• Antibody response in immunocompromised patients with hematologic cancers who received a 3-dose mRNA-1273 vaccination schedule for COVID-19
  Haggenburg S et al. JAMA Oncol, August 2022 (epub ahead of print)
• Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titers
  Susol O et al. Br J Haematol, January 2022 (epub ahead of print) – open access publication
• Serologic responses to COVID-19 vaccines in haematological patients are predominately impaired in lymphoid but not in myeloid malignancies
  Petzer V et al. Hemasphere, February 2022 – open access publication
• Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
  Jiménez M et al. Blood Adv, February 2022 – open access publication

Access 2021 publications on COVID-19 and CML/cancer
Access 2020 publications on COVID-19 and CML/cancer